Stress, immunity, cytokines and depression

Acta Neuropsychiatrica

Volumn 14, Issue 6, 2002, Pages 251-261

  Anisman, Hymie ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

Cytokine; Depression; Immune; Immunotherapy; Interleukin; Post traumatic stress disorder; Stress

Indexed keywords

CYTOKINE;

BEHAVIOR; CENTRAL NERVOUS SYSTEM; DEPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOTHERAPY; INFLAMMATION; MOOD DISORDER; NEUROCHEMISTRY; NEUROENDOCRINE SYSTEM; NEUROLOGIC DISEASE; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; REVIEW; STRESS;

EID: 0036908497     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-5215.2002.140601.x     Document Type: Review

References (99)

1. Banks WA. Cytokines, CVSs, and the blood-brain-barrier. In: ADER R, FELTEN DL, COHEN N, eds. Psychoneuroimmunology, vol. 2. New York: Academic Press, 2001: 483-498.
2. Blalock JE. The syntax of immune-neuroendocrine communication. Immunol Today 1994;15:504-511.
3. Dantzer R, Bluthe RM, Aubert A et al. Cytokine actions on behavior. In: Rothwell NJ, ed. Cytokines and the Nervous System. London: Landes, 1996:117-144.
4. Maier SF, Watkins LR. Cytokines for psychologists. Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998;105:83-107.
5. Quagliarello VJ, Wisplwey B, Long WJ Jr, Sheld WM. Recombinant interleukin-1 induces meningitis and bloodbrain barrier injury in the rat. J Clin Invest 1991;87:1360-1366.
6. Anisman H, Zalcman S, Zacharko RM. The impact of stressors on immune and central transmitter activity: Bidirectional communication. Rev Neurosci 1993;4:147-180.
7. Lopez JF, Akil H, Watson SJ. Neural circuits mediating stress. Biol Psychiatry 1999;46:461-471.
8. McEwen BS. Allostasis and allostatic load. Implications for neuropsychopharmacology. Neuropsychopharmacology 2000;22:108-124.
9. Heim C, Nemenroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: Preclinical and clinical studies. Biol Psychiatry 2001;49:1023-1039.
10. Kalivas P, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 1991;16:223-244.
11. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010.
12. Dhabhar FS. Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking. Ann NY Acad Sci 2000;917:876-893.
13. McEwen BS. The neurobiology of stress: From serendipity to clinical relevance. Brain Res 2000;886:172-189.
14. Sheridan JF, Stark JL, Avitsur R, PADGETT DA. Social disruption, immunity, and susceptibility to viral infection. Role of glucocorticoid insensitivity and NGF. Ann NY Acad Sci 2000;917:894-905.
15. De Groot J, Ruis MA, SCHOLTEN JW, KOOLHAAS JM, Boersma WJ Long-term effects of social stress on antiviral immunity in pigs. Physiol Behav 2001;73:145-158.
16. Tilders FJ, Schmidt ED. Interleukin-l-induced plasticity of hypothalamic CRH neurons and long-term stress hyper-responsiveness. Ann NY Acad Sci 1998;840:65-73.
17. Tilders FJ, Schmidt ED. Cross-sensitization between immune and non-immune stressors. A role in the etiology of depression? Adv Exp Med Biol 1999;461:179-197.
18. Dhabrar FS, MILLER AH, McEwen BS, Spencer RL. Differential activation of adrenal steroid receptors in neural and immune tissues of Sprague Dawley, Fischer 344, and Lewis rats. J Neuroimmunol 1995;56:77-90.
19. Lu ZW, Song C, Ravindran AV, Merali Z, Anisman H. Influence of a psychogenic and a neurogenic stressor on several indices of immune functioning in different strains of mice. Brain Behav Immun 1998;12:7-22.
20. Cohen S, Herbert TB. Health psychology, psychological factors and physical disease from the perspective of human psychoneuroimmunology. Ann Rev Psychol 1996;47:113-142.
21. Cohen S, Miller GE, Rabin BS. Psychological stress and antibody response to immunization: A critical review of the human literature. Psychosom Med 2001;63:7-18.
22. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality: New perspectives from psychoneuroimmunology. Ann Rev Psychol 2002;53:83-107.
23. Marsland AL, Cohen S, Rabin BS, Manuck SB. Associations between stress, trait negative affect, acute immune reactivity, and antibody response to hepatitis B injection in healthy young adults. Health Psychol 2001;20:4-11.
24. Kiecolt-glaser JK, Cacioppo JT, MALARKEY WB, Glaser R. Acute psychological stressors and short-term immune changes: What, why, for whom, and to what extent? Psychosom Med 1992;54:680-685.
25. Marucha PT, Kiecolt-glaser JK, Favagehi M. Mucosal wound healing is impaired by examination stress. Psychosom Med 1998;60:362-365.
26. Glaser R, Kiecolt-Glaser JK, Malarkey WB, Sheridan JF. The influence of psychological stress on the immune response to vaccines. Ann N Y Acad Sci 1998;840:649-655.
27. Cohen S, Doyle WJ, Skoner DP. Psychological stress, cytokine production, and severity of upper respiratory illness. Psychosom Med 1999;61:175-180.
28. Cohen S, Frank E, Doyle WJ, Skoner DP, Rabin BS, Gwaltney JM. Types of stressors that increase susceptibility to the common cold in healthy adults. Health Psychol 1998;17:214-223.
29. Maes M, Van Bockstaele DR, Gastel A et al. The effects of psychological stress on leukocyte subset distribution in humans: Evidence of immune activation. Neuropsychobiology 1999;39:1-9.
30. Maes M, Song C, Lin A et al. The effects of psychological stress on humans: Increased production of pro-inflammatory cytokines and a Thl-like response in stress-induced anxiety. Cytokine 1998;10:313-318.
31. Song C, Kenis G, Van Gastel A et al. Influence of psychological stress on immune-inflammatory variables in normal humans. Part II. Altered serum concentrations of natural anti-inflammatory agents and soluble membrane antigens of monocytes and T lymphocytes. Psychiatr Res 1999;85: 293-303.
32. Kiecolt-Glaser JK, Glaser R, Gravenstein S, MalarKey WB, Sheridan J. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc Natl Acad Sci 1996;93:3043-3047.
33. Redinbaugh Em, MacCallum RC, Kiecolt-Glaser JK Recurrent syndromal depression in caregivers. Psychol Aging 1995;10:358-368.
34. Schulz R, O'brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995;35:771-791.
35. Kiecolt-Glaser JK, Dura JR, Speicher CE, Trask OJ, Glaser R. Spousal caregivers of dementia victims: Longitudinal changes in immunity and health. Psychosom Med 1991;53:345-362.
36. Pearlin LI, Mullan JT, Semple SJ, Skaff MM. Caregiving and the stress process: An overview of concepts and their measures. Gerontologist 1990;30:583-594.
37. Bauer ME, Vedhara K, Perks P, Wilcock GK, Lightman SL, Shanks N. Chronic stress in caregivers of dementia patients is associated with reduced lymphocyte sensitivity to glucocorticoids. J Neuroimmunol 2000;103: 84-92.
38. Esterling BA, Kiecolt-Glaser JK, Glaser R. Psychosocial modulation of cytokine-induced natural killer cell activity in older adults. Psychosom Med 1996;58:264-272.
39. Kennedy S, Kiecolt-Glaser JK, Glaser R. Immunological consequences of acute and chronic stressors: Mediating role of interpersonal relationships. Br J Med Psychol 1988;61:77-85.
40. Glaser R, Sheridan J, Malarkey WB, MacCallum RC, Kiecolt-Glaser JK. Chronic stress modulates the immune response to a pneumococcal pneumonia vaccine. Psychosom Med 2000;62:804-807.
41. Glaser R, Kiecolt-Glaser JK. Chronic stress modulates the virus-specific immune response to latent herpes simplex virus type 1. Ann Behav Med 1997;19:78-82.
42. Vedhara K, Cox NK, Wilcock GK et al. Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. Lancet 1999;353:627-631.
43. Irwin M, Brown M, Patterson T, Hauger R, Mascovich A, Grant I. Neuropeptide Y and natural killer cell activity: Findings in depression and Alzheimer caregiver stress. FASEB J 1991;5:3100-3107.
44. Irwin M, Hauger R, Patterson TL, Semple S, Ziegler M, Grant I. Alzheimer caregiver stress. Basal natural killer cell activity, pituitary-adrenal cortical function, and sympathetic tone. Ann Behav Med 1997;19:83-90.
45. Uchino BN, Cacioppo JT, Kiecolt-glaser JK. The relationship between social support and physiological processes: A review with emphasis on underlying mechanisms and implications for health. Psychol Bull 1996;119:488-531.
46. Vedhara K, Shanks N, Anderson S, Lightman S. The role of stressors and psychosocial variables in the stress process: A study of chronic caregiver stress. Psychosom Med 2000;62:374-385.
47. Pike JL, Smith TL, Hauger RL et al. Chronic life stress alters sympathetic, neuroendocrine, and immune responsivity to an acute psychological stressor in humans. Psychosom Med 1997;59:447-457.
48. Cacioppo JT, Burleson MH, Poehlmann KM et al. Autonomic and neuroendocrine responses to mild psychological stressors: Effects of chronic stress on older women. Ann Behav Med 2000;22:140-148.
49. Yehuda R. Linking the neuroendocrinology of post-traumatic stress disorder with recent neuroanatomic findings. Sem Clin Neuropsychiatry 1999;4:256-265.
50. Yehuda R, McFarlane AC. Conflict between current knowledge about post-traumatic stress disorder and its original conceptual basis. Am J Psychiatry 1995;152:1705-1713.
51. Kawamura N, Kim Y, Asukai N. Suppression of cellular immunity in men with a past history of post-traumatic stress disorder. Am J Psychiatry 2001;158:484-488.
52. Inoue-Sakurai C, Maruyama S, Morimoto K. Post-traumatic stress and lifestyles are associated with natural killer cell activity in victims of the Hanshin-Awaji earthquake in Japan. Prev Med 2000;31:467-473.
53. Everson M P, Kotler S, Blackburn W D Jr. Stress and immune dysfunction in Gulf War veterans. Ann NY Acad Sci 1999;876:413-418.
54. Laudenslager ML, Aasal R, Adler L et al. Elevated cytotoxicity in combat veterans with long-term post-traumatic stress disorder: Preliminary observations. Brain Behav Immun 1998;12:74-79.
55. Weiss D W, Hirt R, Tarcic N et al. Studies in psychoneuroimmunology: Psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behav Med 1996;22:5-14.
56. Sabioncello A, Kocijan-Hercigonja D, Rabatic S et al. Immune, endocrine, and psychological responses in civilians displaced by war. Psychosom Med 2000;62:502-508.
57. Wilson SN, Van Der Kolk B, Burbridge J, Fisler R, Kradin R. Phenotype of blood lymphocytes in PTSD suggests chronic immune activation. Psychosomatics 1999;40: 222-225.
58. Matheson K, Anisman H. Systems of coping associated with psychological distress: A profile perspective. J Abn Psychol 2002 (in press).
59. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25-46.
60. Maes M. Evidence for an immune response in major depression. A review and hypothesis. Progr Neuro-Psychopharmacol Biol Psychiatry 1995;19:11-38.
61. Kronfol Z, House JD. Depression, hypothalamic-pituitary-adrenocortical activity, and lymphocyte function. Psychopharmacol Bull 1985;21:476-478.
62. Irwin M. Immune correlates of depression. Adv Exp Med Biol 1999;461:1-24.
63. Moldofsky H. Sleep and the immune system. Int J Immunopharmacol 1995;17:649-654.
64. Cover H, Irwin M. Immunity and depression: Insomnia, retardation and reduction of natural killer cell activity. J Behav Med 1994;17:217-223.
65. Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;148:337-344.
66. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann NY Acad Sci 1995;771:716-729.
67. Levitan RD, Kaplan AS, Brown GM et al. Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression. Biol Psychiatry 1997;41:366-368.
68. Zaharia MD, Ravindran AV, Griffiths J, Merali Z, Anisman H. Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features. J Affect Disord 2000;58:1-10.
69. Miller AH, Spencer RL, McEwen BS, Stein M. Depression, adrenal steroids, and the immune system. Ann Med 1993;25:481-487.
70. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999;461:199-233.
71. Dunn A J. Interactions between the nervous system and the immune system. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995: 719-731.
72. Dunn AJ. Effects of cytokines and infections on brain neurochemistry. In: ADER R, FELTEN DL, COHEN N, eds. Psychoneuroimmunology. New York: Academic Press, 2001:649-666.
73. Lacosta S, Merali Z, Anisman H. Central monoamine alterations associated with acute and repeated interleukin-2 administration. Neuroimmunomodulation 2000;9:1-16.
74. Song C, Merali Z, Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 1999;88:823-836.
75. Licinio J, Wong L. The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999;4:317-327.
76. Van West D, Maes M. Activation of the inflammatory response system: A new look at the etiopathogenesis of major depression. Neuroendocrinol Lett 1999;20:11-17.
77. Connor TJ, Leonard BE. Depression, stress and immunological activation: The role of cytokines in depressive disorders. Life Sci 1998;62:583-606.
78. Maes M, Scharpe S, Meltzer HY et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatr Res 1993;49:11-27.
79. Maes M, Lambrechts J, Bosmans E et al. Evidence for a systemic immune activation during depression. Results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 1992;22: 45-53.
80. Muller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS. Implications for psychiatric disorders. Prog Neuropsychopharm Biol Psychiatry 1998;22:1-33.
81. Smith RS. The macrophage theory of depression. Med Hypoth 1991;35:298-306.
82. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acad Sci 1995;762:474-476.
83. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999;4:182-188.
84. Anisman H, Ravindran AV, Griffiths J, Merali Z. Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatry 1999;46:1649-1655.
85. Kubera M, Kenis G, Bosmans E et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: Comparison between the acute state and after remission. Pol J Pharmacol 2000;52:237-241.
86. Hayley S, Brebner K, Lacosta S, Merali Z, Anisman H. Sensitization to the effects of tumor necrosis factorα;neuroendocrine, central monoamine and behavioral variations. J Neurosci 1999;19:5654-5665.
87. Anisman H, Kokkinidis L, Merali Z. Influence of interleukin-2 on responding for electrical brain stimulation from the hypothalamus. Brain Res 1996;731:1-11.
88. Yirimaya R, Weidenfeld J, Pollak Y et al. Cytokines, 'depression due to a general medical condition', and antidepressant drugs. Adv Exp Med Biol 1999;461:283-316.
89. Reichenberg A, Yirmiya R, Schuld A et al. Cytokineassociated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452.
90. Bonaccorso S, Marino V, Puzella A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90.
91. Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatr Res 2001;105:45-55.
92. Capuron L, Ravaud A, Gualde N et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001;26:797-808.
93. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2001;63:376-386.
94. Caraceni A, Martini C, Belli F et al. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur J Cancer 1992;29A:1266-1269.
95. Denicoff KD, Rubinow DR, Papa MZ et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Int Med 1987;107: 293-300.
96. Meyers CA, Valentine AD. Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 1995;3:56-68.
97. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999;156:1120.
98. Maes M, Capuron L, Ravaud A et al. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacology 2001;24:130-140.
99. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferon alpha. N Engl J Med 2001;344:961-966.